CRISPR Therapeutics (CRSP) director granted 13,000 options at $51.84 strike

Rhea-AI Filing Summary

CRISPR Therapeutics AG director Katherine A. High received a grant of 13,000 stock options on Common Shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036. They vest in 12 equal monthly installments, beginning June 30, 2026, subject to continued service, with final vesting on the earlier of the one-year anniversary of grant or the 2027 Annual Meeting.

Insights

Equity compensation analyst

Director received routine stock option grant tied to continued service.

Director Katherine A. High was granted stock options for 13,000 Common Shares at an exercise price of $51.84 per share. This award represents equity-based compensation rather than an open-market transaction and aligns the director’s incentives with long-term shareholder value.

The options vest in 12 equal monthly installments starting on June 30, 2026, ending on the earlier of the one-year anniversary of grant or the 2027 Annual Meeting, and expire on June 5, 2036. This staged vesting encourages continued board service and long-term commitment while limiting immediate liquidity.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider High Katherine A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	13,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 13,000 shares (Direct)

Footnotes (1)

1. F1. Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

Key Figures

Options granted: 13,000 options Exercise price: $51.84 per share Expiration date: June 5, 2036 +3 more

6 metrics

Options granted 13,000 options Grant to director Katherine A. High on June 5, 2026

Exercise price $51.84 per share Strike price for granted stock options

Expiration date June 5, 2036 Option term end date

Underlying shares 13,000 Common Shares Shares subject to granted options

Vesting start June 30, 2026 First monthly vesting installment

Vesting schedule length 12 monthly installments From June 30, 2026 to earlier of one-year anniversary or 2027 Annual Meeting

Key Terms

Stock Option (Right to Buy), exercise price, vesting, Common Shares, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "51.8400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"the options will vest and become exercisable in 12 equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Shares financial

"underlying_security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Annual Meeting financial

"the last installment vests on the earlier of ... the date of the 2027 Annual Meeting"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/09/2026 - 06:51 PM Accepted by SEC EDGAR 06/09/2026 - 05:42 PM Learn about SEC filing dates

FAQ

What equity award did CRISPR Therapeutics (CRSP) director Katherine High receive?

Katherine High received a grant of 13,000 stock options on Common Shares. The options function as equity compensation, giving her the right to buy shares at a fixed price if she continues serving the company over time.

What is the exercise price of Katherine High’s CRSP stock options?

The stock options granted to Katherine High have an exercise price of $51.84 per share. This is the fixed price she can pay to buy CRISPR Therapeutics Common Shares if and when the options vest and she chooses to exercise them.

How do Katherine High’s CRISPR Therapeutics options vest over time?

The options vest in 12 equal monthly installments, subject to continued service. Vesting starts on June 30, 2026, with the final installment vesting on the earlier of the one-year anniversary of grant or the date of the 2027 Annual Meeting.

When do Katherine High’s CRSP stock options expire?

The stock options granted to Katherine High expire on June 5, 2036. If she does not exercise them by that date, the options become worthless, so the long term of the award provides an extended potential exercise window.

Is Katherine High’s CRSP transaction a market buy or sell of shares?

No, this transaction reflects a grant of stock options as compensation, not a market purchase or sale. She acquired rights to buy 13,000 Common Shares at a fixed price, contingent on vesting and future exercise decisions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

High Katherine A

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$51.84	06/05/2026		A		13,000		(1)	06/05/2036	Common Shares	13,000	$0	13,000	D

Explanation of Responses:

1. Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

	/s/ Elizabeth Ryland Waldinger	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)